Qualitative or quantitative defects of caveolin-3

Qualitative or quantitative defects of caveolin-3 (also known as caveolinopathies) refer to a group of rare neuromuscular disorders caused by mutations in the CAV3 gene, which encodes the protein caveolin-3. Caveolin-3 is a critical structural component of caveolae — small flask-shaped invaginations of the plasma membrane — in skeletal and cardiac muscle cells. When caveolin-3 is absent, reduced in quantity, or structurally abnormal, it disrupts normal muscle cell signaling and membrane integrity, leading to a spectrum of muscle diseases. The clinical manifestations of caveolin-3 defects are highly variable and can present as several distinct but overlapping phenotypes. These include limb-girdle muscular dystrophy type 1C (LGMD1C), characterized by proximal muscle weakness, calf hypertrophy, and elevated serum creatine kinase (CK) levels; rippling muscle disease, featuring muscle mounding and wave-like contractions of muscles upon mechanical stimulation; distal myopathy; hyperCKemia (persistently elevated CK without overt weakness); and hypertrophic cardiomyopathy, which can sometimes occur in isolation or alongside skeletal muscle involvement. Long QT syndrome type 9 has also been associated with CAV3 mutations, highlighting the cardiac implications of this condition. Diagnosis is typically established through clinical evaluation, elevated serum CK levels, muscle biopsy showing reduced or absent caveolin-3 immunostaining, and confirmed by molecular genetic testing of the CAV3 gene. There is currently no curative treatment for caveolinopathies. Management is supportive and symptom-based, including physical therapy to maintain mobility, cardiac monitoring and management for those with cardiomyopathy or arrhythmias, and avoidance of strenuous exercise in some cases. Genetic counseling is recommended for affected individuals and their families.

Common questions about Qualitative or quantitative defects of caveolin-3